Sodium retention and ascites formation in a cholestatic mice model: Role of aldosterone and mineralocorticoid receptor?

Hepatology

Volumn 46, Issue 1, 2007, Pages 173-179

  Ackermann, Daniel ^a   Mordasini, David ^a   Cheval, Lydie ^a   Imbert Teboul, Martine ^a   Vogt, Bruno ^a   Doucet, Alain ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALDOSTERONE; DEXAMETHASONE; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; SERUM AND GLUCOCORTICOID REGULATED KINASE 1;

ARTICLE; ASCITES; BILE DUCT LIGATION; CONTROLLED STUDY; HYPERALDOSTERONISM; IMMUNOBLOTTING; LIVER CIRRHOSIS; MOUSE; NEPHRON; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SODIUM RETENTION;

ADRENALECTOMY; ANIMALS; CHOLESTASIS; DISEASE MODELS, ANIMAL; HOMEOSTASIS; MALE; MICE; MICE, INBRED STRAINS; NA(+)-K(+)-EXCHANGING ATPASE; NEPHRONS; RECEPTORS, ALDOSTERONE; RECEPTORS, MINERALOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM; URINARY RETENTION;

EID: 34547423958     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21699     Document Type: Article

References (51)

1. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med 1988;319:1127-1134.
2. Bernardi M, Di Marco C, Trevisani F, Fornale L, Andreone P, Cursaro C, Baraldini M, et al. Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology 1993;105:188-193.
3. Graebe M, Brond L, Christensen S, Nielsen S, Olsen NV, Jonassen TE. Chronic nitric oxide synthase inhibition exacerbates renal dysfunction in cirrhotic rats. Am J Physiol Renal Physiol 2004;286:F288-F297.
4. Jimenez W, Martinez-Pardo A, Arroyo V, Bruix J, Rimola A, Gaya J, et al. Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. HEPATOLOGY 1985;5:245-250.
5. Levy M, Allotey JB. Temporal relationships between urinary salt retention and altered systemic hemodynamics in dogs with experimental cirrhosis. J Lab Clin Med 1978;92:560-569.
6. Levy M, Wexler MJ. Renal sodium retention and ascites formation in dogs with experimental cirrhosis but without portal hypertension or increased splanchnic vascular capacity. J Lab Clin Med 1978;91:520-536.
7. Wensing G, Sabra R, Branch RA. The onset of sodium retention in experimental cirrhosis in rats is related to a critical threshold of liver function. HEPATOLOGY 1990;11:779-786.
8. Lieberman FL, Ito S, Reynolds TB. Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value does not account for renal sodium retention, a sponteneous reduction in glomerular filtration rate (GFR), and a fall in GFR during drug-induced diuresis. J Clin Invest 1969;48:975-981.
9. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998;339:533-541.
10. Martin PY, Ohara M, Gines P, Xu DL, St. John J, Niederberger M, et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest 1998;101:235-242.
11. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988;8:1151-1157.
12. Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. HEPATOLOGY 1992;15:323-328.
13. Lopez C, Jimenez W, Arroyo V, Claria J, La Villa G, Asbert M, et al. Temporal relationship between the decrease in arterial pressure and sodium retention in conscious spontaneously hypertensive rats with carbon tetrachloride-induced cirrhosis. HEPATOLOGY 1991;13:585-589.
14. Bernardi M, Servadei D, Trevisani F, Rusticali AG, Gasbarrini G. Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites. Digestion 1985;31:189-193.
15. Campra JL, Reynolds TB. Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites. Am J Dig Dis 1978;23:1025-1030.
16. Gatta A, Angeli P, Caregaro L, Menon F, Sacerdoti D, Merkel C. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. HEPATOLOGY 1991;14:231-236.
17. Gregory PB, Broekelschen PH, Hill MD, Lipton AB, Knauer CM, Egger M, et al. Complications of diuresis in the alcoholic patient with ascites: a controlled trial. Gastroenterology 1977;73:534-538.
18. Angeli P, Dalla Pria M, De Bei E, Albino G, Caregaro L, Merkel C, et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. HEPATOLOGY 1994;19:72-79.
19. Better OS, Schrier RW. Disturbed volume homeostasis in patients with cirrhosis of the liver. Kidney Int 1983;23:303-311.
20. La Villa G, Salmeron JM, Arroyo V, Bosch J, Gines P, Garcia-Pagan JC, et al. Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology 1992;102:2114-2119.
21. Rector WG Jr, Lewis FW, Adair OV, Robertson AD. Plasma renin activity in alcoholic liver disease. Am J Med 1992;92:485-493.
22. Rector WG Jr, Robertson AD, Lewis FW, Adair OV. Arterial underfilling does not cause sodium retention in cirrhosis. Am J Med 1993;95:286-295.
23. Chonko AM, Bay WH, Stein JH, Ferris TF. The role of renin and aldosterone in the salt retention of edema. Am J Med 1977;63:881-889.
24. Bernardi M, Trevisani F, Santini C, De Palma R, Gasbarrini G. Aldosterone related blood volume expansion in cirrhosis before and during the early phase of ascites formation. Gut 1983;24:761-766.
25. Decaux G, Hanson B, Cauchie P, Bosson D, Unger J. Relationship between aldosterone and sodium, potassium, and uric acid clearance in cirrhosis with and without ascites. Nephron 1986;44:226-229.
26. Trevisani F, Bernardi M, De Palma R, Pancione L, Capani F, Baraldini M, et al. Orcadian variation in renal sodium and potassium handling in cirrhosis. The role of aldosterone, Cortisol, sympathoadrenergic tone, and intratubular factors. Gastroenterology 1989;96:1187-1198.
27. Wilkinson SP, Smith IK, Moodie H, Poston L, Williams R. Studies on mineralocorticoid 'escape' in cirrhosis. Clin Sci (Lond) 1979;56:401-406.
28. Funder JW, Pearce PT, Smith R, Smith A. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988;242:583-585.
29. Ackermann D, Vogt B, Escher G, Dick B, Reichen J, Frey BM, et al. Inhibition of 11beta-hydroxysteroid dehydrogenase by bile acids in rats with cirrhosis. HEPATOLOGY 1999;30:623-629.
30. Escher G, Nawrocki A, Staub T, Vishwanath BS, Frey BM, Reichen J, et al. Down-regulation of hepatic and renal 11 beta-hydroxysteroid dehydrogenase in rats with liver cirrhosis. Gastroenterology 1998;114:175-184.
31. Quattropani C, Vogt B, Odermatt A, Dick B, Frey BM, Frey FJ. Reduced activity of 11 beta-hydroxysteroid dehydrogenase in patients with cholestasis. J Clin Invest 2001;108:1299-1305.
32. Thiesson HC, Jensen BL, Bistrup C, Ottosen PD, McNeilly AD, Andrew R, et al. Renal sodium retention in cirrhotic rats depends on glucocorticoid-mediated activation of the mineralocorticoid receptor due to decreased renal 11βHSD2 activity. Am J Physiol Regul Integr Comp Physiol 2006;292:R625-R636.
33. Lopez-Novoa JM, Rengel MA, Hernando L. Sodium excretion after bilateral adrenalectomy in rats with experimental cirrhosis. Experientia 1978;34:1613-1614.
34. Fernandez-Llama P, Ageloff S, Fernandez-Varo G, Ros J, Wang X, Garra N, et al. Sodium retention in cirrhotic rats is associated with increased renal abundance of sodium transporter proteins. Kidney Int 2005;67:622-630.
35. Kim SW, de Seigneux S, Sassen MC, Lee J, Kim J, Knepper MA, et al. Increased apical targeting of renal ENaC subunits and decreased expression of 11betaHSD2 in HgCl2-induced nephrotic syndrome in rats. Am J Physiol Renal Physiol 2006;290:F674-F687.
36. Kim SW, Schou UK, Peters CD, de Seigneux S, Kwon TH, Knepper MA, et al. Increased apical targeting of renal epithelial sodium channel subunits and decreased expression of type 2 11beta-hydroxysteroid dehydrogenase in rats with CCl4-induced decompensated liver cirrhosis. J Am Soc Nephrol 2005;16:3196-3210.
37. Kim SW, Wang W, Nielsen J, Praetorius J, Kwon TH, Knepper MA, et al. Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats. Am J Physiol Renal Physiol 2004;286:F922-F935.
38. Kim SW, Wang W, Sassen MC, Choi KC, Han JS, Knepper MA, et al. Biphasic changes of epithelial sodium channel abundance and trafficking in common bile duct ligation-induced liver cirrhosis. Kidney Int 2006;69:89-98.
39. Yu Z, Serra A, Sauter D, Loffing J, Ackermann D, Frey FJ, et al. Sodium retention in rats with liver cirrhosis is associated with increased renal abundance of NaCl cotransporter (NCC). Nephrol Dial Transplant 2005;20:1833-1841.
40. Jonassen TE, Brond L, Torp M, Graebe M, Nielsen S, Skott O, et al. Effects of renal denervation on tubular sodium handling in rats with CBL-induced liver cirrhosis. Am J Physiol Renal Physiol 2003;284:F555-F563.
41. Jonassen TE, Heide AM, Janjua NR, Christensen S. Collecting duct function in liver cirrhotic rats with early sodium retention. Acta Physiol Scand 2002;175:237-244.
42. Doucet A, Katz AI, Morel F. Determination of Na-K-ATPase activity in single segments of the mammalian nephron. Am J Physiol 1979;237:F105-F113.
43. Cheval L, Duong Van Huyen JP, Bruneval P, Verbavatz JM, Elalouf JM, Doucet A. Plasticity of mouse renal collecting duct in response to potassium depletion. Physiol Genomics 2004;19:61-73.
44. Carranza ML, Feraille E, Favre H. Protein kinase C-dependent phosphorylation of Na(+)-K(+)-ATPase alpha-subunit in rat kidney cortical tubules. Am J Physiol 1996;271:C136-C143.
45. Feraille E, Doucet A. Sodium-potassium-adenosinetriphosphatase-dependent sodium transpott in the kidney: hormonal control. Physiol Rev 2001;81:345-418.
46. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W, et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of Cortisol. J Clin Endocrinol Metab 1979;49:757-764.
47. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987;2:821-824.
48. Stauffer AT, Rochat MK, Dick B, Frey FJ, Odermatt A. Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. J Biol Chem 2002;277:26286-26292.
49. Ecelbarger CA Role of the aldosterone-sensirive distal nephron in the sodium retention associated with livet cirrhosis. Kidney Int 2006;69:10-12.
50. Frey FJ. Impaired 11 beta-hydroxysteroid dehydrogenase contributes to renal sodium avidity in cirrhosis: hypothesis or fact? HEPATOLOGY 2006;44:795-801.
51. Hellal-Levy C, Couette B, Fagart J, Souque A, Gomez-Sanchez C, Rafestin-Oblin M. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Lett 1999;464:9-13.